Gilead to present data for Sovaldi/GS-5816 combo

In an abstract released ahead of an upcoming liver meeting, Gilead Sciences Inc. (NASDAQ:GILD) said once-daily HCV drug Sovaldi sofosbuvir plus GS-5816 for 12 weeks led to a sustained virologic response (SVR) four weeks after the end of treatment in 86-100% of HCV patients in a Phase II trial. The trial enrolled 154 treatment-naïve patients with HCV genotypes 1-6 infection without cirrhosis. Gilead is slated to present data from the trial at the European Association for the Study of the Liver meeting next month. GS-5816 is an oral pan-genotypic HCV NS5A inhibitor, and Sovaldi is a nucleotide analog HCV NS5B polymerase inhibitor. ...